FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313260030> ?p ?o ?g. }

• W4313260030 endingPage "31" @default.
• W4313260030 startingPage "31" @default.
• W4313260030 abstract "Background: Esketamine has been approved by the US Food and Drug Administration (FDA) as an adjunctive treatment for use in conjunction with an oral antidepressant for patients with treatment-resistant depression (TRD), but dissociative symptoms are common adverse effects. Methods: A retrospective analysis of 394 subcutaneous esketamine injections given to 70 patients with TRD that were administered once a week during a six-week trial in conjunction with oral antidepressant therapy. Doses between 0.5 to 1.0 mg/kg were administered according to the patient’s response. Dissociative symptoms were assessed using the Clinician-Administered Dissociative States Scale (CADSS) 30 and 60 min after every weekly treatment (day 1, 8, 15, 22, 29 and 36). Results: Seventy patients received a total of 394 subcutaneous esketamine injections over six weeks. Over time, the evolution of CADSS scores demonstrated a significant mean difference of CADSS at 60 min post-injection (p = 0.010) throughout the six infusions. The mean CADSS scores at 60 min on day 22, 29 and 36 were similar. There were no differences between mean CADSS scores 30 min after the injections, no clinical correlation between response and dissociative symptoms, no correlation between time and demographic and clinical characteristics and no interactions between time and combined medication. Conclusions: Our results suggest that repeated subcutaneous esketamine doses are safe and well-tolerated regarding their acute dissociative and psychotomimetic symptoms. Symptoms usually peak at 30 min and decrease at 60 min post-injection, returning to their pretreatment levels at 120 min. Dissociative symptoms do not correlate with antidepressant response." @default.
• W4313260030 created "2023-01-06" @default.
• W4313260030 creator A5017789434 @default.
• W4313260030 creator A5019309575 @default.
• W4313260030 creator A5030987781 @default.
• W4313260030 creator A5031348440 @default.
• W4313260030 creator A5033669948 @default.
• W4313260030 creator A5046760986 @default.
• W4313260030 creator A5053407427 @default.
• W4313260030 creator A5064926027 @default.
• W4313260030 creator A5087677503 @default.
• W4313260030 date "2022-12-26" @default.
• W4313260030 modified "2023-10-03" @default.
• W4313260030 title "Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression" @default.
• W4313260030 cites W1948877773 @default.
• W4313260030 cites W2023081218 @default.
• W4313260030 cites W2097857685 @default.
• W4313260030 cites W2132324173 @default.
• W4313260030 cites W2141217193 @default.
• W4313260030 cites W2153702524 @default.
• W4313260030 cites W2156342513 @default.
• W4313260030 cites W2328324756 @default.
• W4313260030 cites W2608289281 @default.
• W4313260030 cites W2625860417 @default.
• W4313260030 cites W2741959390 @default.
• W4313260030 cites W2757860301 @default.
• W4313260030 cites W2779386549 @default.
• W4313260030 cites W2793157570 @default.
• W4313260030 cites W2796940952 @default.
• W4313260030 cites W2895197076 @default.
• W4313260030 cites W2946661342 @default.
• W4313260030 cites W2948363033 @default.
• W4313260030 cites W2948816951 @default.
• W4313260030 cites W2961020354 @default.
• W4313260030 cites W2986296475 @default.
• W4313260030 cites W2986913805 @default.
• W4313260030 cites W3004365315 @default.
• W4313260030 cites W3041772408 @default.
• W4313260030 cites W3115413617 @default.
• W4313260030 cites W3120269913 @default.
• W4313260030 doi "https://doi.org/10.3390/ph16010031" @default.
• W4313260030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36678528" @default.
• W4313260030 hasPublicationYear "2022" @default.
• W4313260030 type Work @default.
• W4313260030 citedByCount "2" @default.
• W4313260030 countsByYear W43132600302023 @default.
• W4313260030 crossrefType "journal-article" @default.
• W4313260030 hasAuthorship W4313260030A5017789434 @default.
• W4313260030 hasAuthorship W4313260030A5019309575 @default.
• W4313260030 hasAuthorship W4313260030A5030987781 @default.
• W4313260030 hasAuthorship W4313260030A5031348440 @default.
• W4313260030 hasAuthorship W4313260030A5033669948 @default.
• W4313260030 hasAuthorship W4313260030A5046760986 @default.
• W4313260030 hasAuthorship W4313260030A5053407427 @default.
• W4313260030 hasAuthorship W4313260030A5064926027 @default.
• W4313260030 hasAuthorship W4313260030A5087677503 @default.
• W4313260030 hasBestOaLocation W43132600301 @default.
• W4313260030 hasConcept C126322002 @default.
• W4313260030 hasConcept C139719470 @default.
• W4313260030 hasConcept C142724271 @default.
• W4313260030 hasConcept C162324750 @default.
• W4313260030 hasConcept C197934379 @default.
• W4313260030 hasConcept C204787440 @default.
• W4313260030 hasConcept C27081682 @default.
• W4313260030 hasConcept C2776000289 @default.
• W4313260030 hasConcept C2776390293 @default.
• W4313260030 hasConcept C2776867660 @default.
• W4313260030 hasConcept C2777342061 @default.
• W4313260030 hasConcept C2778807096 @default.
• W4313260030 hasConcept C2779177272 @default.
• W4313260030 hasConcept C2781161787 @default.
• W4313260030 hasConcept C42219234 @default.
• W4313260030 hasConcept C71924100 @default.
• W4313260030 hasConcept C98274493 @default.
• W4313260030 hasConceptScore W4313260030C126322002 @default.
• W4313260030 hasConceptScore W4313260030C139719470 @default.
• W4313260030 hasConceptScore W4313260030C142724271 @default.
• W4313260030 hasConceptScore W4313260030C162324750 @default.
• W4313260030 hasConceptScore W4313260030C197934379 @default.
• W4313260030 hasConceptScore W4313260030C204787440 @default.
• W4313260030 hasConceptScore W4313260030C27081682 @default.
• W4313260030 hasConceptScore W4313260030C2776000289 @default.
• W4313260030 hasConceptScore W4313260030C2776390293 @default.
• W4313260030 hasConceptScore W4313260030C2776867660 @default.
• W4313260030 hasConceptScore W4313260030C2777342061 @default.
• W4313260030 hasConceptScore W4313260030C2778807096 @default.
• W4313260030 hasConceptScore W4313260030C2779177272 @default.
• W4313260030 hasConceptScore W4313260030C2781161787 @default.
• W4313260030 hasConceptScore W4313260030C42219234 @default.
• W4313260030 hasConceptScore W4313260030C71924100 @default.
• W4313260030 hasConceptScore W4313260030C98274493 @default.
• W4313260030 hasIssue "1" @default.
• W4313260030 hasLocation W43132600301 @default.
• W4313260030 hasLocation W43132600302 @default.
• W4313260030 hasLocation W43132600303 @default.
• W4313260030 hasOpenAccess W4313260030 @default.
• W4313260030 hasPrimaryLocation W43132600301 @default.
• W4313260030 hasRelatedWork W2093284812 @default.

• next